Stay updated with breaking news from Surmount 4. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Phase 3 data show patients with obesity who maintained tirzepatide from weeks 36 to 88 continued significant weight loss versus patients switched to placebo.
In this episode, hosts discuss the results of SURMOUNT-3 and SURMOUNT-4 as well as how it might help inform use of tirzepatide if approved by the US Food and Drug Administration for chronic weight management.